InvestorsObserver
×
News Home

Should You Add Kymera Therapeutics Inc (KYMR) Stock to Your Portfolio Tuesday?

Tuesday, March 26, 2024 12:11 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Add Kymera Therapeutics Inc (KYMR) Stock to Your Portfolio Tuesday?

A rating of 83 puts Kymera Therapeutics Inc (KYMR) near the top of the Healthcare sector according to InvestorsObserver. Kymera Therapeutics Inc's score of 83 means that it ranks higher than 83% of stocks in the sector. In addition, its overall score of 85 ranks it higher than 85% of all stocks.

Overall Score - 85
KYMR has an Overall Score of 85. Find out what this means to you and get the rest of the rankings on KYMR!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in the healthcare sector with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Kymera Therapeutics Inc Stock Today?

Kymera Therapeutics Inc (KYMR) stock has fallen -0.16% while the S&P 500 is higher by 0.27% as of 12:10 PM on Tuesday, Mar 26. KYMR has fallen -$0.06 from the previous closing price of $39.50 on volume of 113,859 shares. Over the past year the S&P 500 is higher by 31.55% while KYMR is higher by 36.90%. KYMR lost -$2.52 per share the over the last 12 months. Click Here to get the full Stock Report for Kymera Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App